SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Context Therapeutics announced positive interim efficacy and safety results from a Phase 1 clinical trial for CTIM-76, a bispecific antibody candidate, disclosed under Item 8.01 (Other Events).
View raw filing on EDGAR →Mari J. Baker, a director and Chair of the Executive Compensation and Development Committee, notified the Board on June 10, 2026 of her intent not to stand for reelection at the September 24, 2026 Annual Meeting, completing her 15-year tenure. This is a material departure of a senior board member with significant committee leadership responsibilities, affecting board composition and governance structure.
View raw filing on EDGAR →This Item 8.01 disclosure provides a comprehensive NAV update as of May 31, 2026, including detailed valuation methodologies, property portfolio metrics (55 properties, 95% leased, 30% levered), June 2026 distribution declarations, and disclosure of a recent acquisition (Junction One, £50.0 million / $66.7 million retail property in Liverpool acquired May 15, 2026). While NAV updates are routine for non-traded REITs, the combination of material portfolio information, distribution details, and acquisition disclosure makes this material to investors assessing the registrant's financial position and asset base. The event does not fit neatly into more specific categories (not earnings, not M&A alone, not compensation), warranting classification as other_material.
View raw filing on EDGAR →Allbirds completed the sale of its entire footwear business, including intellectual property, inventory, and customer lists, to Allbirds IP LLC for $40.7 million in cash on June 9, 2026.
View raw filing on EDGAR →Allbirds announced a special dividend to stockholders funded by proceeds from the asset sale, with a record date of June 25, 2026 and payment within 60 days.
View raw filing on EDGAR →The disclosure centers on amendments to Adam K. Bowen's compensatory and employment arrangements as Interim CFO, including modifications to base salary, bonus structure, discretionary cash awards ($100,000 initial plus conditional quarterly awards), and LTI equity vesting terms. While the filing is under Item 5.02, the substantive focus is on compensation modifications rather than a departure or appointment event, making exec_compensation the most precise classification.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Kodiak AI's 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing reports final voting tallies for two proposals: election of two Class I directors (Don Burnette and Kristin Sverchek) and ratification of Deloitte & Touche LLP as independent auditor. This is a textbook Item 5.07 disclosure of shareholder vote results, which is material to investors as it confirms governance outcomes and auditor appointment.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from NewtekOne's Annual Meeting of Shareholders held on June 12, 2026. The filing reports voting outcomes for three proposals: election of two directors (Proposal I), ratification of RSM US LLP as independent auditors (Proposal II), and advisory approval of named executive officer compensation (Proposal III), with detailed vote tallies for each. This is a quintessential Item 5.07 disclosure and is material to investors as it reflects shareholder governance decisions.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Alliance Laundry Holdings' June 11, 2026 annual meeting, covering four proposals: election of Class I directors, ratification of Ernst & Young LLP as independent auditor, advisory vote on compensation vote frequency, and advisory vote on named executive officer compensation. The filing presents final vote tallies for each proposal, which is the core content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Zoom's 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing presents voting results for three proposals: election of Class I directors (Eric S. Yuan and Lieut. Gen. H.R. McMaster), ratification of KPMG LLP as independent auditor, and an advisory vote on named executive officer compensation. The detailed vote tallies (FOR, AGAINST, ABSTAIN, BROKER NON-VOTE) are the core disclosure required by Item 5.07.
View raw filing on EDGAR →Rhythm Pharmaceuticals disclosed interim Phase 2 trial data for setmelanotide in Prader-Willi syndrome and other obesity-related indications, along with multiple clinical data presentations at the Endocrine Society's Annual Meeting (ENDO 2026), including efficacy and safety results showing BMI reductions and improvements in hyperphagia. This material clinical development milestone affects investor assessment of the company's pipeline and commercial prospects but does not fit the standard 8-K event taxonomy.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder vote results from Verde Clean Fuels' 2026 Annual Meeting held on June 12, 2026. The filing reports voting outcomes for two proposals: (1) re-election of Jonathan Siegler as Class III director with 38,174,994 votes for and 337,358 withheld, and (2) ratification of Deloitte & Touche LLP as independent auditor with 40,205,518 votes for and 5,701 against. These are routine but material governance matters that affect board composition and audit oversight.
View raw filing on EDGAR →The filing discloses financial results for the fiscal quarter and year ended April 30, 2026 via a press release attached as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, which is material to investors as it provides quarterly and annual financial performance information.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the June 10, 2026 Annual General Meeting under Item 5.07. The filing reports detailed vote tallies for four proposals: election of seven directors, advisory vote on executive compensation, frequency of advisory compensation votes (approved as annual), and appointment of Grant Thornton LLP as auditor. All material proposals were approved by shareholders.
View raw filing on EDGAR →This Item 8.01 disclosure provides a comprehensive NAV update as of May 31, 2026, showing NAV per share of $8.1908 (up from $8.1640 in April), along with detailed portfolio composition, leverage metrics (31.9%), capital raising activity ($286.6 million quarter-to-date), and updated suitability standards for Washington investors. While NAV updates are routine for non-traded REITs, the material portfolio and valuation information—including sensitivity analyses on cap rates and discount rates—would affect a reasonable investor's assessment of the fund's value and performance. The disclosure does not fit neatly into more specific categories (not earnings, not M&A, not impairment), making "other_material" the appropriate classification.
View raw filing on EDGAR →Mr. Pascal Desroches was appointed as an Independent Director and Audit Committee chair of Honeywell Aerospace Inc., effective June 14, 2026, a material governance change affecting board composition and oversight.
View raw filing on EDGAR →Honeywell completed the spin-off of its Aerospace Technologies business into an independent, publicly traded company with a distribution ratio of 1 share for every 2 Honeywell shares, scheduled for distribution on June 29, 2026, and listing on Nasdaq under ticker 'HONA'.
View raw filing on EDGAR →Eva Boratto, a Board member of UPS, resigned effective immediately on June 13, 2026, due to her appointment as CFO of Cencora, Inc. This is a clear executive departure—a director leaving the Board. Board composition changes are material to investors as they affect governance and oversight. The resignation was not due to disagreement, but the departure itself is the salient disclosed event.
View raw filing on EDGAR →This Item 8.01 disclosure provides a comprehensive NAV update as of May 31, 2026, showing Aggregate Fund NAV of $5,091,114 thousand and NAV per Fund Interest of $13.2898, along with portfolio metrics (276 industrial buildings, 58.4 million square feet, 89.4% occupied) and leverage ratio of 45.1%. While NAV updates are routine for non-traded REITs, this filing includes material portfolio and financial information that would affect investor assessment of the fund's value and performance, including capital raised ($89.8 million quarter-to-date) and redemptions ($54.1 million). The disclosure does not fit neatly into more specific event categories (not earnings, not M&A, not impairment, not going-concern), making "other_material" the appropriate classification.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Rockwell Medical's June 12, 2026 Annual Meeting of Stockholders. The filing presents voting tallies for four proposals: election of Class II directors (Joseph Dawson and Joan Lau, Ph.D.), advisory approval of named executive officer compensation, ratification of EisnerAmper LLP as independent auditor, and approval of a reverse stock split amendment. The materiality is high given the reverse stock split approval and auditor ratification are substantive corporate governance matters affecting investors.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the June 11, 2026 Annual Meeting of Stockholders, filed under Item 5.07. The filing reports final voting tallies for Proposal 1 (election of three Class I directors) and Proposal 2 (ratification of Deloitte & Touche LLP as independent auditor), with specific vote counts for each nominee and proposal. Annual meeting voting results are material to investors as they confirm board composition and auditor appointment.
View raw filing on EDGAR →The filing discloses financial results for Vistagen's fiscal year ended March 31, 2026, via a press release furnished as Exhibit 99.1. This is a classic earnings release disclosure under Item 2.02, which would materially affect a reasonable investor's assessment of the company's financial performance and condition.
View raw filing on EDGAR →Essential Properties Realty Trust closed a $400 million underwritten public offering of senior notes on June 15, 2026, governed by an indenture with Wells Fargo Securities and BofA Securities as underwriter representatives. The offering represents a material capital structure transaction involving entry into definitive debt agreements.
View raw filing on EDGAR →Conversion of approximately 103 million shares of Series Preferred Stock into Class A and Class B common stock in connection with the Company's IPO closing on June 15, 2026, representing a material dilutive event that fundamentally alters the capital structure.
View raw filing on EDGAR →Material modification to rights of security holders and amendments to the Certificate of Formation and Bylaws in connection with the Company's IPO completion on June 15, 2026, reflecting the transition from private to public company status and governance restructuring.
View raw filing on EDGAR →Adoption of amended and restated equity incentive plans (the A&R 2024 Plan and Second A&R ESPP) in connection with the Company's IPO, establishing the framework for compensatory equity awards to directors, officers, and employees with hundreds of millions of shares reserved.
View raw filing on EDGAR →Completion of a major IPO on June 15, 2026, involving 638.9 million shares at $135 per share, raising substantial capital for growth initiatives and representing a transformational capital-raising event.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the June 11, 2026 annual meeting of stockholders, covering three proposals: election of five directors, ratification of auditor Baker Tilly US, LLP, and advisory approval of named executive officer compensation. The filing presents the vote tallies for each proposal, which is the core content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from Sweetgreen's Annual Meeting of Stockholders held on June 11, 2026. The filing reports the final voting tallies for three proposals: (1) election of nine directors, (2) ratification of Deloitte & Touche LLP as independent auditor, and (3) advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, and the disclosure includes detailed vote counts (FOR, AGAINST/WITHHOLD, ABSTAIN, and BROKER NON-VOTES) for each proposal, which is the standard format for shareholder vote results disclosures.
View raw filing on EDGAR →Cushman & Wakefield amended its credit agreement affecting approximately $848 million in outstanding term loans, including repricing, a seven-year maturity extension to 2033, and a $353 million upsizing. Concurrently, the company completed a partial redemption of $350 million of its 6.750% Senior Secured Notes due 2028, reducing outstanding principal from $550 million to $200 million.
View raw filing on EDGAR →Spyre Therapeutics announced positive Phase 2 SKYLINE trial topline results for SPY002 in ulcerative colitis, meeting the primary endpoint with a statistically significant 10.7-point RHI reduction (p<0.0001) and demonstrating a favorable safety profile. This material clinical milestone represents a significant development in the company's pipeline that would affect investor assessment of regulatory prospects and commercial value.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Toast's June 12, 2026 annual meeting of stockholders. The filing presents voting outcomes for three proposals: election of three Class II directors (Kent Bennett, Susan Chapman-Hughes, and Mark Hawkins), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder vote results disclosure.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of Priority Technology Holdings' 2026 annual meeting of stockholders held on June 11, 2026, including voting outcomes on four proposals: election of six directors, approval of an amendment to the equity incentive plan, advisory vote on executive compensation, and ratification of KPMG LLP as auditor. The filing presents vote tallies (For/Against/Abstain/Broker Non-Votes) for each proposal, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →This 6-K discloses FDA approval of Truqap (capivasertib) in combination with abiraterone and prednisone for PTEN-deficient metastatic prostate cancer, based on positive Phase III CAPItello-281 trial results showing a 19% reduction in risk of disease progression or death. This is a material regulatory milestone and product approval event that expands AstraZeneca's oncology portfolio into a second tumor type, representing a significant operational and commercial development rather than a discrete financial, governance, or legal event.
View raw filing on EDGAR →The 6-K discloses HSBC's declaration and payment of a first interim dividend for 2026 of US$0.10 per ordinary share (US$0.50 per ADS), payable on 26 June 2026. This is a routine but material capital distribution to shareholders that would affect investor assessment of capital allocation and shareholder returns.
View raw filing on EDGAR →The filing discloses a press release announcing quarterly financial results for the period ended April 30, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). This is a standard earnings release disclosure, which is material to investors as it provides periodic financial performance information essential to assessing the registrant's financial condition and operating results.
View raw filing on EDGAR →The filing discloses entry into a Vice Chairman Agreement with Mark Iwanowski, appointing him to serve as Vice Chairman in an advisory capacity effective June 12, 2026. Although the position is non-executive and advisory (not a Board seat or officer role under the Exchange Act), the appointment of a high-profile strategic advisor with substantial technology and M&A experience to a named executive-level position is material to investors assessing the company's leadership and strategic direction. The equity compensation structure ($150,000 annual NSOs plus performance-based grants) reinforces the materiality of this appointment.
View raw filing on EDGAR →SUN entered into a Master Services and Digital Platform Agreement with Phoenix Dance Theatre valued at approximately US$350,000 over 36 months. While Item 1.01 typically covers M&A activity (acquisitions, mergers, dispositions), this disclosure describes a material services contract rather than a change of control or acquisition. The agreement is material to investors as it represents a significant multi-year revenue commitment and strategic validation of the Company's business model, but does not constitute a traditional M&A transaction, making "other_material" the most appropriate classification.
View raw filing on EDGAR →The filing discloses entry into a binding Letter of Intent for a material business combination between Nixxy and Tachyon Corporation, with Tachyon valued at approximately $1 billion. The transaction will result in a change of control, with Tachyon shareholders expected to hold at least 90% of the combined company post-closing. This is a classic M&A activity disclosure under Item 1.01, involving a multi-step business combination creating a publicly traded digital infrastructure platform company.
View raw filing on EDGAR →Forward Industries disclosed non-binding acquisition proposals to two companies (SkyAI and Solana Company) made in June 2026, both of which were rejected or expired without response by June 12, 2026. While these are M&A-related disclosures, they involve rejected non-binding proposals rather than entry into, completion of, or termination of a material acquisition agreement, making them fall outside the core M&A activity definition. The disclosure is material to investors as it signals strategic intent and potential capital deployment, but the lack of binding commitment or definitive agreement makes "other_material" the most appropriate classification.
View raw filing on EDGAR →Virgin Galactic held its Annual Meeting on June 11, 2026, with shareholders voting on five proposals including director elections, auditor ratification, say-on-pay, equity plan approval, and say-on-frequency of say-on-pay votes.
View raw filing on EDGAR →Shareholders approved the Fourth Amended and Restated 2019 Incentive Award Plan, which materially expands the equity compensation framework by increasing available shares by 9.45 million and extending the grant period through 2036.
View raw filing on EDGAR →Repay Holdings Corp entered into a First Amendment to its Credit Agreement that materially modifies the Company's debt facilities, including reducing the term loan maturity from June 1, 2033 to June 1, 2032 and revising springing maturity provisions related to the 2.875% Convertible Senior Notes due 2029. These modifications to the Company's debt structure represent material changes to its financing arrangements.
View raw filing on EDGAR →Splash Beverage Group announced a "strategic investment" in Avicanna Inc. via press release on June 15, 2026. While the disclosure is limited and filed under Item 7.01 (Regulation FD Disclosure) rather than the more formal Item 1.01 (Business Combinations), a strategic investment in another company constitutes a material acquisition or investment activity that would affect a reasonable investor's assessment of the registrant's capital allocation and strategic direction. The modest confidence reflects the sparse detail provided and the Item 7.01 classification, which suggests the company may not view this as a formal business combination requiring full Item 1.01 disclosure.
View raw filing on EDGAR →This Item 8.01 disclosure provides a comprehensive NAV update for Invesco Real Estate Income Trust as of May 31, 2026, including detailed breakdowns of NAV per share by class ($26.09–$28.33), valuation methodology, key assumptions (discount rates 7.2%–9.6%, exit cap rates 5.5%–7.3%), and portfolio composition (70 properties, 94% occupancy, 30% leverage). While NAV disclosures are routine for non-traded REITs, this filing is material to investors as it directly affects share pricing, repurchase valuations, and investment decisions. The disclosure does not fit more specific event categories (no earnings release, impairment, going concern, or litigation), making "other_material" the appropriate classification.
View raw filing on EDGAR →The disclosure centers on the appointment of Andrew Taylor as Vice President and Chief Accounting Officer effective August 28, 2026, a material executive position. While S. Denise Sumner's retirement is also disclosed, the filing's substantive focus is on Taylor's appointment with detailed background information (prior PWC experience, credentials, and confirmations of no conflicts). The Chief Accounting Officer role is material to investors' assessment of financial reporting oversight and internal controls.
View raw filing on EDGAR →This Item 5.07 disclosure presents the results of XPEL's 2026 annual meeting of stockholders held on June 10, 2026, including voting outcomes on three matters: election of six directors, ratification of Deloitte & Touche as independent auditor, and advisory approval of named executive officer compensation. The filing directly matches the shareholder_vote_results event type and is material to investors as it documents the formal governance decisions and shareholder approval outcomes at the annual meeting.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Hims & Hers' Annual Meeting of Stockholders held on June 11, 2026. The filing tabulates voting outcomes for three proposals: election of nine directors, ratification of KPMG LLP as independent auditor, and advisory approval of executive compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder vote results disclosure.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Porch Group's annual meeting of stockholders held on June 10, 2026. The filing presents voting tallies for four proposals: election of eight directors (96.8%–98.9% approval), ratification of Grant Thornton LLP as auditor (99.9% approval), advisory approval of named executive officer compensation (93% approval), and adoption of the Employee Stock Purchase Plan (99.8% approval). These results are material to investors as they confirm the composition of the board and key governance decisions.
View raw filing on EDGAR →The Board appointed Andrew Gengos as Chief Financial Officer and Treasurer, effective on or before July 16, 2026, succeeding Mallory Morales in the principal financial officer role. While the disclosure also includes compensatory arrangements (base salary of $530,000, 40% target bonus, and 650,000 option grant), the principal disclosed action is the appointment of a named executive officer to a key financial leadership position. This is material to investors as CFO changes affect financial oversight and strategy.
View raw filing on EDGAR →